Hansa Biopharma AB HNSA

STO: HNSA | ISIN: SE0002148817 27/06/2025

26,94 SEK (+5,15%)

(+5,15%) 27/06/2025

Grafiek Hansa Biopharma AB

Grafiek Hansa Biopharma AB

1 dag1d 5,15%
1 week1w 12,72%
1 maand1m 16,52%
3 maanden3m 19,31%
6 maanden6m -32,65%
1 jaar1j -41,43%
5 jaar5j -83,66%

Hansa Biopharma AB in het nieuws

Toon enkel gratis nieuws

14 mei 2025 · Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS · Persbericht

13 mei 2025 · Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. · Persbericht

24 april 2025 · Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results · Persbericht

21 maart 2025 · Hansa Biopharma publishes 2024 Annual and Sustainability Reports · Persbericht

11 maart 2025 · Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients · Persbericht

5 september 2024 · Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

23 augustus 2024 · Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis · Persbericht

18 juli 2024 · Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update · Persbericht

3 juli 2024 · Hansa Biopharma to host Q2 2024 interim results conference call · Persbericht

28 juni 2024 · Hansa Biopharma: increase in number of shares and votes · Persbericht

Profiel Hansa Biopharma AB

CEO: Soeren Tulstrup

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe